Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 7/20 | 0.35 |
| ▸ | ADH1C | P00326 | 5/20 | 0.33 |
| ▸ | PHGDH | O43175 | 2/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11767385 | 1.00 | ADH1A (0.35) | ADH1AADH1CPHGDHMCOLN3ADH4 | |
| SCHEMBL11636935 | 0.78 | LMNA (0.32) | — | |
| SCHEMBL11082149 | 0.72 | ADH1A (0.41) | ADH1AADH1CPHGDHMCOLN3ADH1B | |
| SCHEMBL303553 | 0.71 | ADH1A (0.40) | ADH1AADH1CPHGDHADH4ADH1B | |
| SCHEMBL7538132 | 0.71 | ADH1A (0.35) | ADH1AADH1CPHGDHADH4ADH1B | |
| SCHEMBL14855292 | 0.71 | ADH1A (0.40) | ADH1AADH1CPHGDHADH4ADH1B | |
| SCHEMBL8745529 | 0.71 | ADH1A (0.40) | ADH1AADH1CPHGDHADH4ADH1B | |
| SCHEMBL10012568 | 0.71 | ADH1A (0.40) | ADH1AADH1CPHGDHADH4ADH1B | |
| SCHEMBL11824045 | 0.71 | PHGDH (0.37) | ADH1AADH1CPHGDHADH4ADH1B | |
| SCHEMBL10013012 | 0.71 | ADH1A (0.40) | ADH1AADH1CPHGDHADH4ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0245505-B2 | TERMINAL-MODIFIED BLOCK COPOLYMER AND COMPOSITION CONTAINING SAID COPOLYMER | ASAHI CHEMICAL IND (JP) | 1996-08-14 | — | — | EP | claimed |
| US-5332784-A | Conjugated diene, vinylaromatic copolymer | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-07-26 | — | — | US | claimed |
| US-4835209-A | Rubber for tire treads and compositions thereof | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-05-30 | — | — | US | claimed |
| EP-0245505-A1 | TERMINAL-MODIFIED BLOCK COPOLYMER AND COMPOSITION CONTAINING SAID COPOLYMER | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-11-19 | — | — | EP | claimed |
| US-4196287-A | Process for the catalytic production of 2-substituted pyridines | LONZA LTD. (CH) | 1980-04-01 | — | — | US | claimed |
| US-11226345-B2 | Antibodies to olanzapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| US-20200399400-A1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | US | disclosed |
| US-10793644-B2 | Antibodies to risperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-06 | — | — | US | disclosed |
| US-10712353-B2 | Antibodies to olanzapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-14 | — | — | US | disclosed |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-06 | — | — | US | disclosed |
| US-4835209-A | Rubber for tire treads and compositions thereof | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-05-30 | — | — | US | disclosed |
| EP-0252992-A1 | Rubber-like polymers for tire treads, a process for their preparation, and compositions containing said polymers | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-01-20 | — | — | EP | disclosed |
| EP-0245505-A1 | TERMINAL-MODIFIED BLOCK COPOLYMER AND COMPOSITION CONTAINING SAID COPOLYMER | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-11-19 | — | — | EP | disclosed |
| US-4529798-A | Reacting the correcponding lithium, sodium, potassium or magnesium halide compound with a aminonitrile compound | JOHN WYETH & BROTHER LIMITED (GB) | 1985-07-16 | — | — | US | disclosed |
| EP-0054384-B1 | PROCESS FOR PREPARING PYRIDINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0054384-A1 | Process for preparing pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1982-06-23 | — | — | EP | disclosed |
| US-4196287-A | Process for the catalytic production of 2-substituted pyridines | LONZA LTD. (CH) | 1980-04-01 | — | — | US | disclosed |
| US-4098791-A | Process for preparing 3-(cyanimino)-3-amino-propionitriles | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793644-B2 | Antibodies to risperidone haptens and use thereof | HTR4, HTR3C, OPRL1 | ADH1A 1013/4885ADH1C 949/4885PHGDH 4471/4885 |
| US-11225527-B2 | Antibodies to paliperidone haptens and use thereof | LY96, OPRL1, HTR3C | ADH1A 408/4885ADH1C 387/4885PHGDH 3619/4885 |
| US-11226345-B2 | Antibodies to olanzapine haptens and use thereof | HTR4, HTR3C, HTR1A | ADH1A 550/4885ADH1C 564/4885PHGDH 4163/4885 |
| US-10712353-B2 | Antibodies to olanzapine haptens and use thereof | HTR4, HTR3C, HTR1A | ADH1A 550/4885ADH1C 564/4885PHGDH 4163/4885 |
| US-20200399400-A1 | ANTIBODIES TO RISPERIDONE HAPTENS AND USE THEREOF | HTR4, HTR3C, OPRL1 | ADH1A 1013/4885ADH1C 949/4885PHGDH 4471/4885 |
| US-20200040107-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | ADH1A 912/4885ADH1C 995/4885PHGDH 3604/4885 |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | ADH1A 912/4885ADH1C 995/4885PHGDH 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.